transcriptomics

Decipher will remain a wholly owned subsidiary of Veracyte, which plans to integrate Decipher's urologic cancer tests on its nCounter platform.

Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.

The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January. 

The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.

The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.